Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2006

01-06-2006

Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional Study

Authors: Sandra L. Wong, MD, Donald L. Morton, MD, John F. Thompson, MD, Jeffrey E. Gershenwald, MD, Stanley P. L. Leong, MD, Douglas S. Reintgen, MD, Haim Gutman, MD, Michael S. Sabel, MD, Grant W. Carlson, MD, Kelly M. McMasters, MD, PhD, Douglas S. Tyler, MD, James S. Goydos, MD, Alexander M. M. Eggermont, MD, PhD, Omgo E. Nieweg, MD, PhD, A. Benedict Cosimi, MD, Adam I. Riker, MD, Daniel G. Coit, MD

Published in: Annals of Surgical Oncology | Issue 6/2006

Login to get access

Abstract

Background

Completion lymph node dissection (CLND) is considered the standard of care in melanoma patients found to have sentinel lymph node (SLN) metastasis. However, the therapeutic utility of CLND is not known. The natural history of patients with positive SLNs who do not undergo CLND is undefined. This multi-institutional study was undertaken to characterize patterns of failure and survival rates in these patients and to compare results with those of positive-SLN patients who underwent CLND.

Methods

Surgeons from 16 centers contributed data on 134 positive-SLN patients who did not undergo CLND. SLN biopsy was performed by using each institution’s established protocols. Patients were followed up for recurrence and survival.

Results

In this study population, the median age was 59 years, and 62% were male. The median tumor thickness was 2.6 mm, 77% of tumors had invasion to Clark level IV/V, and 33% of lesions were ulcerated. The primary melanoma was located on the extremities, trunk, and head/neck in 45%, 43%, and 12%, respectively. The median follow-up was 20 months. The median time to recurrence was 11 months. Nodal recurrence was a component of the first site of recurrence in 20 patients (15%). Nodal recurrence–free survival was statistically insignificantly worse than that seen in a contemporary cohort of patients who underwent CLND. Disease-specific survival for positive-SLN patients who did not undergo CLND was 80% at 36 months, which was not significantly different from that of patients who underwent CLND.

Conclusions

This study underscores the importance of ongoing prospective randomized trials in determining the therapeutic value of CLND after positive SLN biopsy in melanoma patients.
Literature
1.
Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–9PubMed
2.
Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976–83PubMed
3.
McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 2002;9:137–41CrossRefPubMed
4.
Reeves ME, Delgado R, Busam KJ, et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 2003;10:27–31CrossRefPubMed
5.
Sabel MS, Gibbs JF, Cheney R, et al. Evolution of sentinel lymph node biopsy for melanoma at a National Cancer Institute-designated cancer center. Surgery 2000;128:556–63CrossRefPubMed
6.
Starz H, Balda BR, Kramer KU, et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001;91:2110–21CrossRefPubMed
7.
Gershenwald JE, Berman RS, Porter G, et al. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol 2000;7:226–31CrossRefPubMed
8.
Pidhorecky I, Lee RJ, Proulx G, et al. Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol 2001;8:109–15PubMed
9.
Chao C, Wong SL, Ross MI, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002;184:520–4; discussion 525CrossRefPubMed
10.
Lee RJ, Gibbs JF, Proulx GM, et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000;46:467–74CrossRefPubMed
11.
Clary BM, Mann B, Brady MS, et al. Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol 2001;8:328–37PubMed
12.
Essner R, Conforti A, Kelley MC, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999;6:442–9CrossRefPubMed
13.
Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253–60PubMed
14.
Weijer C, Shapiro SH, Cranley Glass K. For and against: clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. BMJ 2000;321:756–8CrossRefPubMed
15.
Reintgen D, Pendas S, Jakub J, et al. National trials involving lymphatic mapping for melanoma: the Multicenter Selective Lymphadenectomy Trial, the Sunbelt Melanoma Trial, and the Florida Melanoma Trial. Semin Oncol 2004;31:363–73CrossRefPubMed
Metadata
Title
Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional Study
Authors
Sandra L. Wong, MD
Donald L. Morton, MD
John F. Thompson, MD
Jeffrey E. Gershenwald, MD
Stanley P. L. Leong, MD
Douglas S. Reintgen, MD
Haim Gutman, MD
Michael S. Sabel, MD
Grant W. Carlson, MD
Kelly M. McMasters, MD, PhD
Douglas S. Tyler, MD
James S. Goydos, MD
Alexander M. M. Eggermont, MD, PhD
Omgo E. Nieweg, MD, PhD
A. Benedict Cosimi, MD
Adam I. Riker, MD
Daniel G. Coit, MD
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.03.058

Other articles of this Issue 6/2006

Annals of Surgical Oncology 6/2006 Go to the issue

OriginalPaper

Trends in Hospital and Surgeon Volume and Operative Mortality for Cancer Surgery

OriginalPaper

Consensus Statement on Surgery Journal Authorship – 2006

OriginalPaper

Tumor Bed Boost Omission After Negative Re-Excision in Breast-Conservation Treatment

Review

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

OriginalPaper

Prognostic Score in Gastric Cancer: The Importance of a Conjoint Analysis of Clinical, Pathologic, and Therapeutic Factors

OriginalPaper

Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer